BERLIN and SEATTLE, March 20, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company, announced that Prof. Dr. Matthias Ebert, gastroenterologist at the renowned University Hospital of the Technical University of Munich, Germany, presented results of collaborative clinical studies within the company’s Colorectal Cancer Screening Test Development Program at the Cambridge Healthtech Institute’s inaugural conference “Epigenomics” in San Diego, CA, U.S.A. yesterday.
